On November 20, 2024, Lawrence Jasinski, a Director at LeMaitre Vascular Inc (LMAT, Financial), sold 198 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns 5,111 shares of the company.
LeMaitre Vascular Inc is a provider of medical devices and implants for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons.
Over the past year, Lawrence Jasinski has sold a total of 5,308 shares and has not purchased any shares. The insider transaction history for LeMaitre Vascular Inc shows that there have been 0 insider buys and 18 insider sells over the past year.
On the day of the recent sale, shares of LeMaitre Vascular Inc were trading at $103.5, giving the stock a market cap of $2,427.595 million. The company's price-earnings ratio stands at 59.00, which is higher than the industry median of 28.98 and also higher than the company’s historical median price-earnings ratio.
With a trading price of $103.5 and a GF Value of $66.26, LeMaitre Vascular Inc has a price-to-GF-Value ratio of 1.56, indicating that the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow that the stock has traded at. It also includes a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
